Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Fludarabine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 6/20 | 0.82 |
| ▸ | P2RY1 | P47900 | 8/20 | 0.73 |
| ▸ | P2RY11 | Q96G91 | 5/20 | 0.73 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.73 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.73 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL899922 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL3511 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL17541855 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL8401646 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL13046080 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL482449 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL23884975 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL14565620 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL21173132 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL30350656 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119868554-A | Application of NAT10 as target spot in diagnosis and treatment of NAT10 high expression acute myelogenous leukemia | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-04-25 | — | — | CN | disclosed |
| WO-2025074271-A1 | MYT1 INHIBITORS FOR THE TREATMENT OF CANCERS HARBORING REPLICATION STRESS MUTATIONS | REPARE THERAPEUTICS INC. (CA) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024251736-A1 | COMBINATIONS COMPRISING AN ATR INHIBITOR WITH SYNERGISTIC EFFECT AGAINST GLIOMAS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2024-12-12 | — | — | WO | disclosed |
| EP-4473972-A1 | COMBINATIONS COMPRISING AN ATR INHIBITOR WITH SYNERGISTIC EFFECT AGAINST GLIOMAS | Eberhard-Karls-Universität Tübingen (DE) | 2024-12-11 | — | — | EP | disclosed |
| US-12109221-B2 | Combination therapy for treating cancer | LEUKOS BIOTECH, S.L. (ES) | 2024-10-08 | — | — | US | disclosed |
| WO-2024152052-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | AREVA PHARMACEUTICALS INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024152052-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | AREVA PHARMACEUTICALS INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230122940-A1 | COMBINATION THERAPY FOR TREATING CANCER | LEUKOS BIOTECH, S.L. (ES) | 2023-04-20 | — | — | US | disclosed |
| US-11446321-B2 | Combination therapy for treating cancer | LEUKOS BIOTECH, S.L. (ES) | 2022-09-20 | — | — | US | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| US-20090074704-A1 | Multi-Arm Polymer Prodrugs | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090074704-A1 | Multi-Arm Polymer Prodrugs | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| US-20080194612-A1 | Multi-arm polymer prodrugs | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194612-A1 | Multi-arm polymer prodrugs | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | BCL9, BCL9L, BCL6B | CA5A 2139/4885NT5E 577/4885P2RY1 3797/4885 |
| US-20080194612-A1 | Multi-arm polymer prodrugs | PAICS, CD38, ENTPD3 | CA5A 1500/4885NT5E 540/4885P2RY1 285/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | CA5A 4715/4885NT5E 1964/4885P2RY1 3337/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | CA5A 3955/4885NT5E 724/4885P2RY1 779/4885 |
| US-20090074704-A1 | Multi-Arm Polymer Prodrugs | PAICS, CD38, ENTPD1 | CA5A 1471/4885NT5E 661/4885P2RY1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.